T he epithelial-mesenchymal transition (EMT) is a reversible developmental process, whereby epithelial cells lose cell-cell adhesion and apical-basolateral polarity, while acquiring a mesenchymal front-back polarity and increased cellular invasiveness (1). During metastatic tumor progression, this developmental program becomes reactivated to confer tumor cells with enhanced migratory and invasive properties (2, 3). The opposing process of mesenchymal-epithelial transition (MET) reestablishes the epithelial state, as demonstrated by formation of epithelial tissues and organs in development and by metastatic colonization of epithelial tumors to distant organs (4). Understanding the molecular mechanisms controlling EMT, and the reverse process of MET, is important for development of new therapeutic strategies for the prevention and treatment of metastatic cancer and many other diseases such as organ fibrosis and impaired wound healing (5).
T he epithelial-mesenchymal transition (EMT) is a reversible developmental process, whereby epithelial cells lose cell-cell adhesion and apical-basolateral polarity, while acquiring a mesenchymal front-back polarity and increased cellular invasiveness (1) . During metastatic tumor progression, this developmental program becomes reactivated to confer tumor cells with enhanced migratory and invasive properties (2, 3) . The opposing process of mesenchymal-epithelial transition (MET) reestablishes the epithelial state, as demonstrated by formation of epithelial tissues and organs in development and by metastatic colonization of epithelial tumors to distant organs (4) . Understanding the molecular mechanisms controlling EMT, and the reverse process of MET, is important for development of new therapeutic strategies for the prevention and treatment of metastatic cancer and many other diseases such as organ fibrosis and impaired wound healing (5) .
Cells undergoing EMT maintain the same genomic background in both mesenchymal and epithelial states, but during the progression of EMT, the gene expression profile significantly changes. The onset of EMT involves the repression of epitheliumspecific genes and activation of mesenchyme-specific genes (6) . Changes in promoter-specific DNA methylation altered expression of microRNAs (miRNAs) and enhanced expression of the transcription factors Snail, Slug, and Twist contribute to the induction of EMT (7, 8) . We recently defined a signaling network involving mitogen-activated protein kinase kinase kinase 4 (MAP3K4) and Jun N-terminal protein kinase (JNK) whose inhibition reprograms epithelial tissue stem cells to undergo an EMT (9) . MAP3K4/JNK-mediated phosphorylation of the histone acetyltransferase CBP stimulated acetylation of specific lysine marks in histones H2A/H2B that served to maintain an epithelial phenotype. Loss of MAP3K4/JNK activation of CBP promoted EMT in these tissue stem cells. This study was the first to demonstrate how loss of histone H2A/H2B acetylation could induce cells to lose the epithelial phenotype and enter EMT (9) . Gene expression analysis of epithelial stem cells entering EMT and the claudinlow subtype of triple-negative breast cancer discovered a statistically significant intersecting EMT gene signature (9) . Claudin-low triple-negative breast cancers characteristically have EMT features, are resistant to therapy, and demonstrate a propensity to metastasize to the lung and brain parenchyma (10) (11) (12) (13) .
On the basis of the gene signature derived from the overlapping epithelial stem cell and claudin-low breast cancer expression profiles, we hypothesized that the 140 genes upregulated in the EMT signature functioned to promote the mesenchymal phenotype. Using SUM149 and SUM229 breast cancer cells that exist in culture as dual populations of epithelial cell adhesion molecule-negative (EpCAM Ϫ ) (mesenchymal-like) and EpCAM ϩ/high (epithelial-like) cells, we designed a phenotypic RNA interference (RNAi) screen to identify individual genes whose targeted knockdown in EpCAM Ϫ cells promoted the EpCAM ϩ/high epithelial phenotype (13) (14) (15) . Using this RNAi strategy, the SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c was identified as a novel regulator of EMT. While small interfering RNA (siRNA)-mediated knockdown of Smarcd3/Baf60c induced a MET in EpCAM SUM149 and SUM229 cells, expression of Smarcd3/Baf60c in human mammary epithelial cells (HMECs) promoted EMT. Smarcd3/Baf60c activated the EMT program in HMECs by epigenetic induction of Wnt5a signaling. These results define Smarcd3/ Baf60c as important for maintenance of the EMT properties and mesenchymal phenotype of claudin-low EpCAM Ϫ SUM149 and SUM229 breast cancer cells.
MATERIALS AND METHODS
Cell lines, culture conditions, constructs, and transfections. The primary HMEC line, immortalized using the retrovirus pBabe-hygrohTERT (hygro stands for hygromycin, and hTERT stands for human telomerase reverse transcriptase), was cultured as previously described (16) . SUM149 and SUM229 breast cancer cells were cultured in HuMEC medium (Life Technologies; catalog no. 12752-010) containing 5% fetal bovine serum (FBS), 1% penicillin and streptomycin (PS) plus bovine pituitary extract and HuMEC supplement or Ham's F-12 medium containing 5% FBS, 1% PS plus 5 g/ml insulin and 1 g/ml hydrocortisone, respectively. 293T cells were cultured in Dulbecco's modified Eagle's high-glucose medium with 10% FBS and 1% PS. Transfection of 293T cells was performed in 15-cm dishes for 24 h with Lipofectamine Plus (Invitrogen) according to the manufacturer's specifications. The Smarcd3/Snail/Slug Gateway entry plasmid was subcloned into a lentiviral FLAG-Gateway destination vector. The lentiviral FLAG-Gateway destination vector was a kind gift from Ben Major.
Lentivirus production and infections of HMECs. To produce replication-incompetent lentivirus, 293T cells were cotransfected with either pGIPZ empty vector, FLAG-Smarcd3/Snail/Slug lentiviral Gateway constructs in combination with pMD2.G and psPAX2 (Addgene) using Lipofectamine Plus reagent (Invitrogen). Twenty-four hours later, the cell medium was changed. Viral supernatants were harvested at 48 h posttransfection by ultracentrifugation, and viral pellets were resuspended in 300 l base medium. HMECs were infected overnight with 100 l lentivirus in 6 g/ml Polybrene. Puromycin (3 g/ml) was used to select transduced cells. Selection was complete 7 days after infection. Expression of Smarcd3/Snail/Slug was measured by quantitative reverse transcription-PCR (qRT-PCR).
Fluorescence-activated cell sorting (FACS). Cells were trypsinized and filtered into single-cell suspensions, resuspended in Hanks' balanced salt solution containing 2% FBS (HF medium), and incubated with antibodies for 30 min at 4°C. Cells were stained with the following antibodies, antibodies directed against EpCAM-FITC (EpCAM conjugated to fluorescein isothiocyanate [FITC] ) (catalog no. 10109; Stem Cell Technologies), EpCAM-APC (EpCAM conjugated to allophycocyanin [APC]) (catalog no. 347200; BD), Cd49f-PE-Cy5 (Cd49f conjugated to phycoerythrin [PE] and Cy5) (catalog no. 551129; BD), Cd44-APC (catalog no. 559942; BD), or Cd24-FITC (catalog no. 555427; BD). Unbound antibodies were washed from cells using HF medium. For analytical flow, cells were fixed with 3% paraformaldehyde and analyzed using a BeckmanCoulter CyAn instrument. For sterile live-cell flow cytometry, cells were sorted using a Sony iCyt/reflection instrument.
RNAi screening conditions, immunofluorescence, and high-content imaging. For the RNAi screen, EpCAM Ϫ SUM149 or SUM229 cells were reverse transfected in fibronectin-coated 96-well plates (Greiner) with 25 nM siRNA smart pools (Dharmacon) containing the combination of 4 different siRNA oligonucleotides for each target or control gene (siRNA targeting ubiquitin B [siUBB] for siRNA knockdown efficiency; siRNA targeting glyceraldehyde-3-phosphate dehydrogenase [siGAPDH] for a negative control; siRNA targeting Snail and Slug [siSnail/Slug] for a positive control). Target genes were plated in duplicate on three replicate plates, and control genes were plated 2 times for UBB, 6 times for GAPDH, and 8 times for Snail/Slug on three replicate plates. After 6 days in culture, cells were fixed with 3% paraformaldehyde, permeabilized with 0.1% Triton X, and stained with nuclear 4=,6=-diamidino-2-phenylindole (DAPI) stain, EpCAM (catalog no. 01420; Stem Cell Technologies) and E-cadherin (catalog no. 3195S; Cell Signaling) antibodies. EpCAM (conjugated to secondary Alexa Fluor 555) and E-cadherin (conjugated to secondary Alexa Fluor 488) fluorescence was measured using the highcontent BD Pathway 855 microscope system. Changes in EpCAM and E-cadherin expression were quantitatively measured on a single-cell basis as a function of the percent change in cellular fluorescence using the CellProfiler image analysis software. Results were the compilation of two independent screens performed in triplicate.
Confocal imaging. ZO-1 (catalog no. 33 -9100; Invitrogen) immunofluorescence experiments were conducted with an Olympus FluoView 1000 laser scanning confocal microscope with 40ϫ UPLFLN 1.3-numerical-aperture (NA) oil objective with lasers at 405 and 488 nm. Single z-plane images of Alexa Fluor 488 and DAPI channels (1ϫ or 2.4ϫ zoom) were acquired sequentially with identical laser transmissivity and photomultiplier tube (PMT) voltage settings, and 4-frame Kalman averaging.
Western blotting of whole-cell and nuclear lysates. Whole-cell and nuclear lysates were isolated as previously described (17 ChIP assays. Chromatin immunoprecipitation (ChIP) assays were performed as previously described (9) . ChIP assays were quantified by real-time PCR using ABsolute blue SYBR green PCR mix (Thermo Scientific) and the Applied Biosystems Fast 7500 real-time PCR system. Fold enrichment was determined by the 2 Ϫ⌬CT method. PCR primers were designed to amplify approximately 75-to 100-bp fragments from genomic DNA using Primer Express 3.0 (Applied Biosystems). ChIPqRT-PCR primers include the following: Cdh1 sense (5=-ACCCCCTCTC AGTGGCGT-3=) and antisense (5=-GGAGCGGGCTGGAGTCTG); Cd44 sense (5=-AGTGGATGGACAGGAGGATG-3=) and antisense (5=-T TATGTCCTTCTGGGCTCT); Cldn4 sense (5=-TCAGCCTTCCAGGTC CTCAA-3=) and antisense (5=-CCCCATGGAGGCCATTG-3=); Wnt5a sense (5=-CCTATTTTGCTCCCCGTT-3=) and antisense (5=-AAGAGTC AGCCCCAAATT-3=).
Invasion assays. Cells were plated on growth factor-reduced Matrigel (BD Biosciences)-coated 8-m-pore Transwell chambers. After 24 h, invasion assays were terminated. Noninvading cells were removed from the top of the Transwells by washing and swabbing. Invasive cells were quantified by fixing chambers in 3% paraformaldehyde for 10 min and staining with nuclear DAPI stain. For each Transwell, five 10ϫ fields were imaged and counted.
Real-time qRT-PCR. qRT-PCR was performed as previously described (9) .
Agilent gene expression microarrays. Transfected and control HMEC lines were profiled as described previously using 44,000 (44K) human oligonucleotide microarrays (Agilent Technologies, Santa Clara, CA, USA) (13, 18) . The probes or genes for all analyses were filtered by requiring the lowest normalized intensity values in both sample and control to be Ͼ10. The normalized log 2 ratios (Cy5 sample/Cy3 control) of probes mapping to the same gene (Entrez identification [ID] as defined by the manufacturer) were averaged to generate independent expression estimates. At least three biological replicates were used for each transfected gene (i.e., each Cy5 sample). For Cy3 controls, we used the empty vector cell line, which was the same for all samples. All microarray data are available in the University of North Carolina (UNC) Microarray Database (https://genome.unc.edu/).
Gene signatures.
The previously published claudin-low predictor and the differentiation score were evaluated as previously described (13) . For each infected HMEC line (i.e., Smarcd3, Slug and Snail), we derived a gene signature by performing a one-class significance analysis of microarrays (SAM) with a false discovery rate of 0%. The resulting gene lists can be found in Table S4 in the supplemental material. An enrichment score for each individual signature (up-and downregulated genes combined) was evaluated in the previously published UNC337 data set (GSE18229) of breast cancer samples representing all the intrinsic molecular subtypes. To do so, we calculated the inner product of each signature (gene ratio) and the gene expression value of each breast tumor sample. Subtype calls in the UNC337 data set were used as provided in Gene Expression Omnibus (GEO) (13) .
Statistical analysis. Gene overlap between two signatures was estimated using exact hypergeometric probabilities implemented in R package (http://cran.r-project.org). All microarray cluster analyses were displayed using Java Treeview version 1.1.4r2. Average-linkage hierarchical clustering was performed using Cluster v3.0 (19) .
Microarray data accession number. All microarray data have been deposited in the GEO database under accession number GSE40145. Pools of four independent siRNA oligonucleotides were used to individually target the 140 upregulated genes within the EMT gene signature shared by epithelial stem cells developmentally entering EMT and claudin-low breast cancer (see Table S1 in supplemental material) (9) . With the exception of Slug, Twist, vimentin, and N-cadherin, these genes are uncharacterized with respect to EMT.
RESULTS

SUM149 and
As proof of principle for the RNAi screening strategy, we silenced known EMT-inducing genes Snail and Slug and measured the increase in epithelial markers EpCAM and E-cadherin by immunofluorescence ( Fig. 2C and D) . These experiments demonstrated that siRNA-mediated knockdown of Snail or Slug in the mesenchymal EpCAM Ϫ SUM149 cells resulted in increased EpCAM and E-cadherin expression, loss of the mesenchymal phenotype, and gain of the epithelial phenotype within 6 days posttransfection ( Fig. 2C to E) . At 6 days posttransfection, control GAPDH siRNA-treated EpCAM Ϫ cells had a background of less than 3% EpCAM-or E-cadherin-positive cells ( Fig. 2C and D) . In contrast, dual knockdown of Snail and Slug resulted in 26 and 10% EpCAM or E-cadherin-positive SUM149 cells, respectively (Fig. 2D) . A highly reproducible 3-to 5-fold change in EpCAM and E-cadherin percent fluorescence was observed with siRNAmediated knockdown of Slug or Snail versus control GAPDH knockdown (Fig. 2D) .
The RNAi screen targeted 140 upregulated genes within the EMT gene signature and identified 10 genes whose individual knockdown resulted in the morphological transition between EpCAM Ϫ and EpCAM ϩ/high phenotypes in both SUM149 and SUM229 cells ( Fig. 2F ; see Table S2 in supplemental material). Compared to control GAPDH siRNA knockdown, siRNA-mediated knockdown of these 10 EMT regulatory genes demonstrated a statistically significant increase in the percent EpCAM and E-cadherin cellular fluorescence ( Fig. 3A and B) . The 10 identified EMT regulatory genes included the following: Slug, Cdh2, Smarcd3/Baf60c, ABR, Rnf130, EphA4, Met, Ptprb, Fhl1, and RRAGD ( Fig. 3A to D ; see Table S3 in supplemental material for gene functions). In addition to upregulation of EpCAM and E-cadherin protein expression, siRNA-mediated knockdown of these EMT regulatory genes induced morphological changes characteristic of an epithelial, cobblestone morphology.
Of the 10 EMT regulatory genes identified in the phenotypic RNAi screen, five genes, including Cdh2, Smarcd3/Baf60c, Fhl1, Rnf130, and RRAGD were upregulated in the mesenchymal EpCAM Ϫ cells relative to the epithelial EpCAM ϩ/high SUM149 and SUM229 cells (Fig. 4A) . Deconvolution of siRNA oligonucle- otide pools for each of the 10 genes showed efficient knockdown of the EMT regulatory target genes by at least two of the four oligonucleotides, consistent with increases in EpCAM and E-cadherin expression being the result of on-target knockdown (Fig. 4B) . Functionally, knockdown of ABR, Cdh2, Smarcd3/Baf60c, or Slug expression resulted in significant decreases in cellular invasiveness through growth factor-reduced Matrigel ( Fig. 4C ; see Table S3 in supplemental material). RNAi knockdown of several of the EMT regulatory genes induced a decrease in mRNA expression of the EMT-inducing transcription factors Snail and Slug ( Fig. 4D and E; see Table S3 ). Thus, the RNAi screen effectively identified genes whose selective loss was sufficient to promote the epithelial phenotype of SUM149 and SUM229 breast cancer cells. Smarcd3/Baf60c is an epigenetic regulator of EMT. Of the EMT regulatory genes identified in the screen, RNAi silencing of the SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c in EpCAM Ϫ breast cancer cells gave the most robust transition from the mesenchymal to epithelial phenotype. Smarcd3/Baf60c has the potential to affect a broad network of genes through its epigenetic regulatory function as a member of the SWI/SNF chromatin-remodeling complex (20) (21) (22) (23) . The specificity of the Smarcd3/ Baf60c knockdown was demonstrated by rescue of the EpCAM Ϫ phenotype by transfection of a siRNA resistant to knockdown ( Fig. 5A and B) , indicating that the increases in EpCAM and Ecadherin expression resulted from targeted Smarcd3/Baf60c knockdown and not an off-target response to the siRNA.
To determine its role in the regulation of EMT, FLAG-tagged Smarcd3/Baf60c was stably expressed in human mammary epithelial cells (HMECs) at levels comparable to mesenchymal EpCAM Ϫ SUM149 cells (Fig. 5C ). HMECs expressing Smarcd3/Baf60c (D3-HMECs) demonstrated phenotypic changes indicative of EMT (Fig. 5D ). D3-HMECs lost their epithelial cell morphology and became mesenchymal cell-like, with diminished expression of epithelial cell-cell adhesion markers EpCAM and E-cadherin and gain of expression of the mesenchymal marker vimentin (Fig. 5D) . Western blotting confirmed the decreased expression of EpCAM and Ecadherin with gain of fibronectin and vimentin (Fig. 5E ). Of the EMT-inducing transcription factors, Lef1 and Zeb2 mRNAs were increased compared to empty vector control HMECs (EVHMECs) (Fig. 5F) . Furthermore, the epithelial cell-cell adhesion genes E-cadherin, EpCAM, Krt7, Krt19, Cldn4, and Cldn7 were downregulated (Fig. 5F) . Notably, mRNA expression of the tight junction genes Cldn4 and Cldn7 was reduced 90% compared to EV-HMECs. EV-HMECs and D3-HMECs when analyzed by FACS, profiled as separate cellular populations based on antigenic expression levels of epithelial differentiation markers EpCAM/ Cd49f and breast cancer stem cell markers Cd44/Cd24. Compared to EV-HMECs, the D3-HMECs demonstrated a reduction in the epithelial integrin Cd49f and gain in the prometastatic glycoprotein Cd44 with no change in the prodifferentiation glycoprotein Cd24 (Fig. 5G) . D3-HMECs also showed increased cytoplasmic staining of the tight junctions protein zona occludins (ZO-1) compared to EV-HMECs (Fig. 5H) . The changes in ZO-1 staining were accompanied with a loss of epithelial cobblestone morphology and tight junctions (Fig. 5H) . These results support the role of Smarcd3/Baf60c as an EMT-inducing chromatin-remodeling factor that promotes loss of the epithelial phenotype by a reduction in cell-cell adhesions with gain of the mesenchymal phenotype.
Smarcd3/Baf60c expression in HMECs induces a claudinlow gene signature. We performed gene arrays to measure expression changes in D3-HMECS relative to EV-HMECs. Additionally, we compared gene expression changes of D3-HMECS with Snailand Slug-expressing HMECs (Snail-HMECs and Slug-HMECs, respectively) to define gene networks important for EMT. Hierarchical cluster analysis of gene array data from D3-, Slug-, and Snail-HMECs with respect to the 9-cell line claudin-low predictor described by Prat et al. (13) revealed that the gene expression profiles of D3-HMECs clustered similarly to the claudin-low signature of human breast cancer ( Fig. 6A and B ; see Table S4 in supplemental material). Conversely, the gene expression profiles of Slug-and Snail-HMECs demonstrated substantially less overlap with the claudin-low signature ( Fig. 6A and B ; see Table S4 ). Of the D3-, Slug-, and Snail-HMECs, D3-HMECs had the most significant gene intersection (P value Ͻ 0.0001) with the claudinlow signature sharing 7% upregulated and 13% downregulated genes ( Fig. 6B ; see Table S4 ). D3-and Slug-HMECs shared a significant gene intersection (P value Ͻ 0.0001) with 41% upregulated and 18% downregulated shared genes ( Fig. 6C ; see Table S4 ), suggesting that Smarcd3/Baf60c and Slug affect an overlapping EMT gene network. To further emphasize the significance of the D3-HMEC/claudin-low association, the gene expression profile of D3-HMECs was compared to the five intrinsic molecular subtypes of human breast tumors catalogued in the UNC337 data set. Tumors from the claudin-low subtype showed highest expression of the D3-HMEC signature in comparison with basal-like, HER2-enriched, luminal A and luminal B tumors (Fig. 6D) . The differentiation predictor described by Prat et al. (13) , which uses gene expression profiles to determine the cellular relatedness to the normal breast epithelial differentiation hierarchy from mammary stem cells (MaSCs) to mature luminal cells showed that D3-HMECs had the lowest differentiation score compared to Slugand Snail-HMECs (Fig. 6E) (24) . This suggests that D3-HMECs profile more similarly to MaSCs and more importantly to a lessdifferentiated mesenchymal, claudin-low phenotype than Slugand Snail-HMECs. Collectively, these findings demonstrate that Smarcd3/Baf60c induces an EMT gene expression program in HMECs similar to that of the claudin-low breast cancer subtype.
Molecular characterization of the Smarcd3/Baf60c-induced EMT in HMECs showed a more profound phenotypic conversion than that of the Snail-or Slug-induced EMT in HMECs. Morphological changes included a loss of cell-cell adhesions in D3-HMECs, whereas Snail-and Slug-HMECs maintained a partial degree of epithelial cell-cell adhesions through either E-cadherin or EpCAM expression (Fig. 7A) . Immunofluorescence, Western blotting, and qRT-PCR analysis of D3-and Slug-HMECs showed decreased E-cadherin and increased vimentin, N-cadherin, and fibronectin expression (Fig. 7A to C) , while Snail-HMECs had preferentially decreased EpCAM expression (Fig. 7A and B) . Both Snail-and Slug-HMECs had a 2-to 4-fold increase in Smarcd3/ Baf60c mRNA expression (Fig. 7C) . Snail-and Slug-HMECs also had increased mRNA levels for the EMT-inducing transcription factor Zeb2 similar to Smarcd3/Baf60c (Fig. 5F and 7D ). Like D3-HMECs, Slug-HMECs preferentially repressed the cell-cell adhesion tight junction genes Cldn4 and Cldn7, possibly contributing to the disruption of epithelial cell polarity (Fig. 7E) . Cumulatively, these findings suggest that Smarcd3/Baf60c and Slug impact an overlapping EMT network.
SWI/SNF complex regulates WNT signaling through induction of Wnt5a expression. Wnt5a regulates cellular polarity and cell-cell adhesion through activation of noncanonical WNT signaling pathways (25) (26) (27) . Expression of Wnt5a was upregulated in two independent D3-HMEC lines ( Fig. 8A ; see Table S4 in supplemental material). Activation of Wnt5a-regulated signaling pathways in D3-HMECs was demonstrated by increased PKC␤ phosphorylation and expression of TGF␤ ( Fig. 8A and B) . Nuclear localization of ␤-catenin was decreased in the D3-HMECs, suggesting decreased ␤-catenin function associated with Smarcd3/ Baf60c expression (Fig. 8B) . The ATP-dependent catalytic components of multisubunit SWI/SNF chromatin-remodeling complexes are either Brm or Brg1 (20) . In D3-HMECs, Brg1 expression was increased and coimmunoprecipitated with FLAG-Smarcd3/Baf60c (Fig. 8C and  D) . Chromatin immunoprecipitation (ChIP) assays were used to determine whether the Brg1/Smarcd3/Baf60c complex resided on the Wnt5a gene promoter (Fig. 8E) . Brg1 regulates transcription of E-cadherin and Cd44 (28), so we used these genes as controls for ChIP assays. Smarcd3/Baf60c and Brg1 bound to the promoters of E-cadherin, Cd44, and Wnt5a genes but not to the promoter of the Cldn4 gene ( Fig. 8E and F) . Parallel ChIP assays for the histone methylation mark H3K4me3, which correlates with active transcription, showed loss of this histone mark on the promoters of repressed E-cadherin and Cldn4 genes and gain on the promoters of induced Cd44 and Wnt5a genes (Fig. 7G) . Cumulatively, the findings indicate that Smarcd3/Baf60c and Brg1 bind the Wnt5a promoter for the activation of Wnt5a transcription.
Inhibition of Wnt5a restores the epithelial phenotype. Similar elevation of Wnt5a expression was observed in Slug-HMECs and EpCAM Ϫ SUM149 and SUM229 cells, supporting a role for Wnt5a in the induction of EMT in these cells with upregulated Smarcd3/Baf60c expression ( Fig. 9A and B) . To determine whether Wnt5a was responsible for inducing the loss of epithelial characteristics resulting from Smarcd3/Baf60c expression, we inhibited Wnt5a expression using RNAi in D3-HMECs. siRNA-mediated knockdown of Wnt5a phenotypically converted mesenchymal-like cells lacking cell-cell adhesions to epithelial colonies with a cobblestone morphology (Fig. 9C) . Wnt5a knockdown resulted in the increased mRNA and protein expression of epithelial markers E-cadherin and EpCAM ( Fig. 9D and E) . Although expression of epithelial tight junction genes Cldn4 and Cldn7 was reduced by 90% in D3-HMECs relative to EV-HMECs (Fig. 5F ), knockdown of Wnt5a in D3-HMECs resulted in a 10-fold increase in Cldn4 and Cldn7 (Fig. 9D) . The EMT-inducing transcription factor Lef1 and the mesenchymal marker vimentin, which were each induced with Smarcd3/Baf60c expression ( Fig. 5D and E), were repressed with knockdown of Wnt5a (Fig. 9D) . Knockdown of Wnt5a repressed PKC␤ phosphorylation, consistent with inhibition of the WNT signaling pathway (Fig. 9E) . Treatment of D3-HMECs with a Wnt5a blocking antibody inhibited cellular invasiveness by 70% compared to untreated D3-HMECs (Fig. 9F) , demonstrating that the phenotypic changes coincided with functional changes indicative of a more epithelial cell state. Functionally, the blocking an- 
DISCUSSION
We describe a directed phenotypic RNAi screen that identified genes whose individual knockdown was sufficient to promote MET in the EpCAM Ϫ population of SUM149 and SUM229 breast cancer cells. While it has long been accepted that EMT is a reversible process during development, few studies have examined the opposite process of MET (3, 5) . Our RNAi screen targeted 140 genes from an EMT gene signature shared by epithelial stem cells developmentally entering EMT and claudin-low breast cancer cells with properties of EMT and stemness (9) . Ten of the 140 genes were identified as EMT regulatory genes, whose individual siRNA-mediated knockdown was sufficient to promote MET. Three of the genes, Slug, Met receptor tyrosine kinase, and Ncadherin, are well-defined regulators of EMT and provide validation of the screen (1). The other seven genes have no defined role in EMT. The functions of the seven genes do suggest their potential importance in the phenotypic reprogramming associated with EMT. For instance, EphA4 and Ptprb/VE-Ptp represent a receptor tyrosine kinase and phosphatase, respectively, that in development have been shown to be critical regulators of angiogenesis (29) (30) (31) (32) . Fhl1 localizes to focal adhesions where it promotes cell spreading in a TGF␤-dependent manner, and Rnf130 is a ring finger protein with putative E3 ligase activity (33) (34) (35) (36) (37) . Consistent with its knockdown inhibiting invasion of mesenchymal EpCAM Ϫ SUM149 cells, ABR is a guanine nucleotide exchange factor (GEF)/GTPase-activating protein (GAP) for Rho and Cdc42 GTPases, and RRAGD is a poorly characterized GTPase with homology to Ras (38) (39) (40) (41) . Among these genes, Rnf130 is an interesting gene candidate for future studies with respect to EMT. Our preliminary findings have demonstrated that combined knockdown of Rnf130, Slug, and Smarcd3/Baf60c produced synergistic effects in promoting an epithelial morphology in fully mesenchymal claudin-low SUM159 breast cancer cells. As a putative E3 ligase, there are no defined substrates for ubiquitination by Rnf130. The findings are suggestive that these genes, in addition to Slug, Met, N-cadherin, and Smarcd3/Baf60c, are likely members of a signaling network controlling EMT.
We demonstrated that Smarcd3/Baf60c is a novel epigenetic EMT regulatory gene. Smarcd3/Baf60c was the only gene identified in the RNAi screen whose knockdown strongly increased both EpCAM and E-cadherin expression, decreased Snail and Slug expression, inhibited invasiveness, and was also upregulated in EpCAM Ϫ cells relative to EpCAM ϩ/high SUM149 and SUM229 breast cancer cells. Smarcd3/Baf60c as a member of the multisubunit ATP-dependent SWI/SNF chromatin-remodeling complex has the ability to epigenetically modulate gene expression programs (20, 21) . Smarcd3/Baf60c induced an EMT gene expression program in HMECs, indicating that Smarcd3/Baf60c plays an important role in promoting the EMT properties and mesenchymal phenotype of these cells. Consistent with their related roles as transcriptional regulators, siRNA-mediated knockdown of Slug induced a MET similar to inhibition of Smarcd3/Baf60c expression. Notably, ectopic expression of either Smarcd3/Baf60c or Slug similarly induced the expression of Wnt5a, suggesting that Smarcd3/Baf60c affects an EMT gene network that overlaps with the EMT-inducing function of Slug. To our knowledge, this is the first report of Smarcd3/Baf60c promoting an epigenetic reprogramming event responsible for inducing an EMT in HMECs. Also, Smarcd3/Baf60c maintains the mesenchymal phenotype in claudin-low EpCAM Ϫ populations of SUM149 and SUM229 cells. There is an expanding awareness that SWI/SNF chromatinremodeling complexes play critical functions in reprogramming events relevant to EMT and lineage commitment. Brg1, one of the catalytic components of SWI/SNF chromatin-remodeling complex, is important in the reprogramming of somatic cells to induced pluripotent stem (iPS) cells (42, 43) . MET was shown recently to occur simultaneously with the reprogramming of fibroblasts to iPS cells, directly connecting MET to iPS cell generation (44). Our results indicate that studies are warranted to determine whether Smarcd3/Baf60c expression is repressed in these cells as a switch to induce MET during iPS cell reprogramming. In the context of regulating EMT and MET, WNT signaling has been shown to be an important collaborator with TGF␤ for inducing EMT. WNT signaling, for example, contributes to the metastatic progression of pancreatic cancer and melanoma (45) (46) (47) . In D3-HMECs, we showed that both Smarcd3/Baf60c and Brg1 bind the promoters of Wnt5a and E-cadherin. Wnt5a expression is in- duced, stimulating WNT signaling, while E-cadherin expression is repressed to promote EMT. Together, these findings show the importance of Smarcd3/Baf60c in controlling the commitment to the mesenchymal cellular phenotype. Further studies are warranted to determine the function of SWI/SNF-regulated epigenetic changes that contribute to the claudin-low subtype of breast cancer.
